Webster Bank N. A. Sells 844 Shares of Danaher Co. (NYSE:DHR)

Webster Bank N. A. decreased its holdings in shares of Danaher Co. (NYSE:DHR) by 1.8% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 45,772 shares of the conglomerate’s stock after selling 844 shares during the period. Danaher accounts for about 1.1% of Webster Bank N. A.’s holdings, making the stock its 18th largest holding. Webster Bank N. A.’s holdings in Danaher were worth $10,507,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also bought and sold shares of DHR. FMR LLC grew its position in shares of Danaher by 15.8% in the 3rd quarter. FMR LLC now owns 23,617,424 shares of the conglomerate’s stock worth $6,566,116,000 after buying an additional 3,217,631 shares during the period. Massachusetts Financial Services Co. MA increased its stake in shares of Danaher by 17.6% during the third quarter. Massachusetts Financial Services Co. MA now owns 3,582,982 shares of the conglomerate’s stock valued at $996,141,000 after purchasing an additional 535,254 shares in the last quarter. International Assets Investment Management LLC lifted its holdings in shares of Danaher by 40,196.5% during the third quarter. International Assets Investment Management LLC now owns 429,964 shares of the conglomerate’s stock valued at $119,539,000 after purchasing an additional 428,897 shares during the last quarter. Montrusco Bolton Investments Inc. increased its position in Danaher by 30.4% during the 3rd quarter. Montrusco Bolton Investments Inc. now owns 1,705,884 shares of the conglomerate’s stock valued at $465,617,000 after buying an additional 397,671 shares in the last quarter. Finally, Union Bancaire Privee UBP SA bought a new stake in Danaher in the fourth quarter worth $74,551,000. Hedge funds and other institutional investors own 79.05% of the company’s stock.

Wall Street Analysts Forecast Growth

DHR has been the topic of several recent analyst reports. Wolfe Research raised shares of Danaher from a “peer perform” rating to an “outperform” rating and set a $285.00 price objective on the stock in a research report on Thursday, October 31st. Royal Bank of Canada lowered their price objective on Danaher from $333.00 to $311.00 and set an “outperform” rating on the stock in a research report on Wednesday, October 23rd. Stephens reissued an “overweight” rating and issued a $315.00 target price on shares of Danaher in a report on Wednesday, October 23rd. Guggenheim began coverage on shares of Danaher in a research note on Thursday, December 19th. They set a “buy” rating and a $275.00 target price on the stock. Finally, StockNews.com downgraded Danaher from a “buy” rating to a “hold” rating in a research note on Saturday, December 14th. Six equities research analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $285.55.

Danaher Trading Up 0.1 %

Shares of DHR opened at $245.95 on Monday. The firm has a market cap of $177.65 billion, a P/E ratio of 46.94, a price-to-earnings-growth ratio of 4.43 and a beta of 0.83. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.37 and a quick ratio of 1.01. Danaher Co. has a 1 year low of $225.42 and a 1 year high of $281.70. The company has a 50 day simple moving average of $235.33 and a two-hundred day simple moving average of $253.62.

Danaher Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, January 31st. Shareholders of record on Friday, December 27th will be issued a $0.27 dividend. The ex-dividend date of this dividend is Friday, December 27th. This represents a $1.08 dividend on an annualized basis and a yield of 0.44%. Danaher’s dividend payout ratio is currently 20.61%.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.